16 papers today – this is getting to be a big job. Naloxone, fentanyl, methadone,
stars, pain, Central Asia, primary care, injection facilities, personal stories
…
Centers for Disease
Control and Prevention (CDC).
MMWR Morb Mortal Wkly Rep.
2013 Aug 30;62(34):703-4.
Comment:
The evidence of synthetic fentanyl was difficult to detect and concerning to
many as heralding a possible repeat of the 2006/2007 fentanyl-tainted heroin
overdose outbreak.
Saifan C, Glass D, Barakat
I, El-Sayegh S.
Case Rep Med.
2013;2013:242730. doi: 10.1155/2013/242730. Epub 2013 Jul 29.
Comment:
In this case the patient was restarted on methadone and the sensorineural
hearing loss was permanent.
Chaparro LE, Furlan AD,
Deshpande A, Mailis-Gagnon A, Atlas S, Turk DC.
Cochrane Database Syst
Rev. 2013 Aug 27;8:CD004959. doi:
Comment:
There are no quality data to support long-term management of non-cancer pain
with opioids.
Willens JS.
Pain Manag Nurs. 2013
Sep;14(3):125. doi: 10.1016/j.pmn.2013.07.004. No abstract available.
Comment:
The Glee star.
Shadnia S, Rahimi M,
Hassanian-Moghaddam H, Soltaninejad K, Noroozi A.
Clin Toxicol (Phila). 2013
Aug 23. [Epub ahead of print]
Comment: Accidental
poisonings among family in Iran for (insufficiently-labeled) take-home
methadone syrup.
Teo A, Cooper J.
Scott Med J. 2013
Aug;58(3):149-53. doi: 10.1177/0036933013496951.
Comment: I’m
unable to access this paper. It’s a review of overdose events at a Scottish
hospital; 4% were administered naloxone.
Gilbert L, Primbetova S,
Nikitin D, Hunt T, Terlikbayeva A, Momenghalibaf A, Ruziev M, El-Bassel N.
Drug Alcohol Depend. 2013 Aug 13. doi:pii:
S0376-8716(13)00282-2.
Comment: A
really interesting approach to thinking about HIV and drug overdose mortality,
through the lens of syndemics – a hot topic in public health – and risk
environments. With the bonus of an important review of data from several
Central Asian states.
Bernstein HG, Trübner K,
Krebs P, Dobrowolny H, Bielau H, Steiner J, Bogerts B.
Acta Histochem. 2013 Aug
13. doi:pii: S0065-1281(13)00145-1.
Comment: Interesting
analysis comparing heroin overdose patients to controls, although I’m unclear
it’s direct relationship to the pathologic processes of overdose.
Heimer R, Barbour R,
Palacios WR, Nichols LG, Grau LE.
AIDS Behav. 2013 Aug 7.
[Epub ahead of print]
Comment: Intriguing
paper on rural heroin use.
Chahua M, Sordo L, Barrio
G, Domingo-Salvany A, Brugal MT, Molist G, de la Fuente L, Bravo MJ.
Eur Addict Res. 2013 Aug
1;20(1):1-7. [Epub ahead of print]
Comment: There
haven’t been many overdose studies out of Spain. Nice to see this.
Bowman S, Eiserman J,
Beletsky L, Stancliff S, Bruce RD.
Am J Med. 2013
Jul;126(7):565-71. doi: 10.1016/j.amjmed.2012.11.031. Epub 2013 May 8. Review.
Comment: Kudos
to the authors for getting out to primary care providers information on simple
harm reduction practices that can be employed in clinical settings.
Taylor R Jr, Pergolizzi JV
Jr, Porreca F, Raffa RB.
Expert Opin Investig
Drugs. 2013 Apr;22(4):517-25. doi: 10.1517/13543784.2013.778973. Review.
Comment: Fascinating
paper on the analgesic properties of opioid ANTagonists.
Jozaghi E, Andresen MM.
Harm Reduct J. 2013 Feb
16;10:1. doi: 10.1186/1477-7517-10-1.
Comment: A
discussion including the benefits of supervised injection facilities in
reducing overdose deaths, sharing of injection equipment, public drug use, and
utilization of emergency medical services.
Algren DA, Monteilh CP,
Punja M, Schier JG, Belson M, Hepler BR, Schmidt CJ, Miller CE, Patel M,
Paulozzi LJ, Straetemans M, Rubin C.
J Med Toxicol. 2013
Mar;9(1):106-15. doi: 10.1007/s13181-012-0285-4.
Comment: A
review of pathological details related to the tragic 2005-2007 fentanyl-tainted
heroin outbreak.
15) 'I
saved a life': a heroin addict's
reflections on managing an overdose
using 'take home naloxone'.
George S, Boulay S, Begley
D.
BMJ Case Rep. 2010 Sep
7;2010. doi:pii: bcr0520102986.
Comment: A
rare example in the medical literature, this paper includes several paragraphs
of direct patient perspective on administering naloxone. Read the free
full-text from BMJ.
Reece AS.
BMJ Case Rep. 2010 Sep 7;2010.
doi:pii: bcr0420102871. 10.1136/bcr.04.2010.2871. Review.
Comment: The
hepatotoxicity concerns with naltrexone were based on doses of around 2 grams,
which would be considered massive today.
No comments:
Post a Comment